Skip to main content

Table 2 Baseline characteristics at treatment initiation

From: Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort

Parameters Variables Total number Percentages
Total number   50  
Age (years), median (range)   58 (27–87)  
  ≥ 65 years 14 28%
Sex
  male 31 62%
  female 19 38%
ECOG PS
  0 6 12%
  1 20 40%
  ≥ 2 12 24%
  unknown 12 24%
Primary tumour localisation
  Gastric 27 54%
  Gastroesophageal junction 23 46%
Resection of primary tumour
  yes 25 50%
  no 25 50%
Perioperative therapy
  yes 24 48%
  no 26 52%
Number of previous palliative therapy lines
  0 7 14%
  1 10 20%
  2 19 38%
  ≥ 3 14 28%
Number of subsequent palliative therapy lines
  0 37 74%
  1 7 14%
  ≥ 2 6 12%
Time point of metastases detection
  synchronous 25 50%
  metachronous 25 50%
Site of metastases 1 Peritoneum 17 34%
  Lung 11 22%
  Liver 25 50%
  Other 39 78%
Histologic subtype (Lauren classification)
  intestinal 21 42%
  diffuse or signet ring cell 12 24%
  unspecified 17 34%
HER-2 status
  positive 8 16%
  negative 40 80%
  unknown/missing 2 4%
Microsatellite status
  MSI 8 16%
  MSS 31 62%
  unknown/missing 11 22%
PD-L1 expression
  positive (CPS ≥1 or TPS ≥1%) 24 48%
  negative 13 26%
  unknown/missing 13 26%
  1. 1 Multiple designations possible